泌尿生殖領域聯合研究與授權交易：2016-2024

本報告調查了泌尿生殖領域的聯合研究和授權交易，包括2016年以來的合約趨勢資訊、泌尿生殖領域的聯合研究和授權交易、基準分析 - 交易的市場價值、財務狀況和主要摘要交易金額、最活躍的交易撮合者等。

目錄

執行摘要

第1章 - 簡介

第2章 泌尿生殖區交易趨勢

• 簡介
• 泌尿生殖領域的長期合作趨勢
• 泌尿生殖領域的合作關係，依交易類型
• 泌尿生殖領域的合作關係，依工業領域
• 泌尿生殖領域的合作關係，依發展階段
• 泌尿生殖領域的合作關係，依技術類型
• 泌尿生殖領域的合作關係，依治療適應症分類

第3章 - 有關泌尿生殖聯盟的金融交易條件

• 簡介
• 已揭露的泌尿生殖聯盟的財務條款
• 泌尿生殖領域聯盟的頭條價值
• 泌尿生殖領域交易的預付款
• 泌尿生殖領域交易的里程碑付款
• 泌尿生殖領域交易的特許權使用費率

第4章 - 主要泌尿生殖區交易與交易人員

• 簡介
• 最活躍的合作是在泌尿生殖領域。
• 泌尿生殖領域最活躍的交易撮合者名單
• 泌尿生殖領域的熱門交易

第5章 - 泌尿生殖區合約文件目錄

• 簡介
• 可簽訂合約的泌尿生殖領域合作夥伴交易

第6章 依治療目標劃分的泌尿生殖區域的交易

• 簡介
• 依泌尿生殖治療目標劃分的交易
• 交易目錄
• 交易目錄 - 泌尿生殖道交易，依公司劃分（2016-2024年）
• 交易目錄 - 依技術類型劃分的泌尿生殖道交易（2016-2024年）
• 交易類型的定義
• 關於Biopharma Research Ltd
• 目前的合作關係
• 當前合約
• Current Partnering的最新報告標題

Genitourinary Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genitourinary deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 281 genitourinary deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genitourinary dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in genitourinary dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the genitourinary field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in genitourinary dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of genitourinary deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of genitourinary deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in genitourinary deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genitourinary Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse genitourinary collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genitourinary Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genitourinary trends and structure of deals entered into by leading biopharma companies worldwide.

Genitourinary Collaboration and Licensing Deals includes:

• Trends in genitourinary dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of genitourinary deal records covering pharmaceutical and biotechnology
• The leading genitourinary deals by value
• Most active genitourinary licensing dealmakers

In Genitourinary Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Genitourinary Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

• 2.1. Introduction
• 2.2. Genitourinary partnering over the years
• 2.3. Genitourinary partnering by deal type
• 2.4. Genitourinary partnering by industry sector
• 2.5. Genitourinary partnering by stage of development
• 2.6. Genitourinary partnering by technology type
• 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 - Financial deal terms for genitourinary partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for genitourinary partnering
• 3.3. Genitourinary partnering headline values
• 3.4. Genitourinary deal upfront payments
• 3.5. Genitourinary deal milestone payments
• 3.6. Genitourinary royalty rates

Chapter 4 - Leading genitourinary deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in genitourinary partnering
• 4.3. List of most active dealmakers in genitourinary
• 4.4. Top genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

• 5.1. Introduction
• 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by genitourinary therapeutic target
• Deal directory
• Deal directory - Genitourinary deals by company A-Z 2016 to 2024
• Deal directory - Genitourinary deals by technology type 2016 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genitourinary partnering since 2016
• Figure 2: Genitourinary partnering by deal type since 2016
• Figure 3: Genitourinary partnering by industry sector since 2016
• Figure 4: Genitourinary partnering by stage of development since 2016
• Figure 5: Genitourinary partnering by technology type since 2016
• Figure 6: Genitourinary partnering by indication since 2016
• Figure 7: Genitourinary deals with a headline value
• Figure 8: Genitourinary deals with upfront payment values
• Figure 9: Genitourinary deals with milestone payment
• Figure 10: Genitourinary deals with royalty rates
• Figure 11: Active genitourinary dealmaking activity since 2016
• Figure 12: Top genitourinary deals by value since 2016